Johnson & Johnson (NYSE:JNJ) reported 48-week results from its Phase 3 FUZION study evaluating Tremfya (guselkumab) in adults with Crohn’s disease and active perianal fistulas, showing that fistula ...
Add Yahoo as a preferred source to see more of our stories on Google. The decision provides a new therapeutic option for patients with r/r MM. Credit: luchschenF / Shutterstock.com. The European ...
PRNewswire/ -- (NYSE: JNJ) today announced new two-year results from the Phase 3 ICONIC-LEADa study evaluating ICOTYDE® (icotrokinra), ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
If approved, TALVEY® plus daratumumab will be the only GPRC5D-targeting bispecific antibody combination therapy for relapsed or refractory multiple myeloma as early as second lineCHMP recommendation ...
On Tuesday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson’s JNJ IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA). The agency cleared the medication ...
The survey was released ahead of the American Urological Association (AUA) Annual Meeting. (Sheldon Cooper/SOPA Images/LightRocket via Getty Images) A new survey undertaken by the Harris Poll for ...
The European Commission (EC) has approved an extended use of Johnson & Johnson's Tecvayli (teclistamab), along with daratumumab, to treat adult patients with relapsed or refractory multiple myeloma (r ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results